Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy

This study is currently recruiting participants.
Verified January 2012 by Clinique Romande de Readaptation
Sponsor:
Collaborator:
Swiss Paraplegic Centre Nottwil
Information provided by (Responsible Party):
Bertrand LEGER, Clinique Romande de Readaptation
ClinicalTrials.gov Identifier:
NCT01470950
First received: September 21, 2011
Last updated: January 30, 2012
Last verified: January 2012
  Purpose

Atrogin-1 and muscle RING finger-1 are skeletal muscle specific genes, with ubiquitin ligase activities, that are upregulated during muscle atrophy in mice. Atrogin-1 and MuRF1 knock-out mice have a significant protection against skeletal muscle atrophy. The Akt/GSK3 and Akt/mTOR pathways are involved in muscle hypertrophy in mice. They have also been shown to stimulate the expression of myogenic regulatory factors. Recent studies by the investigators team and others have demonstrated the implication of these signalling pathways in the control of muscle mass in humans. However no study has yet investigated the involvement of these systems in the early stages of spinal cord injury induced human skeletal muscle atrophy.

Goals of the project The investigators propose to investigate the level of expression of the different components of the ubiquitin-proteasome system together with the level of expression and activity of the Akt/mTOR and Akt/GSK3 signalling pathways after SCI in humans during the first months following the injury.

Moreover the investigators will also study the effects of exercise training in paraplegic patients on the same molecular targets. In order to do that the investigators will use a novel apparatus of electrical stimulation which generate movements by closed-loop electrical muscle stimulation.

Detailed research plan The patients will be recruited jointly at the Clinique Romande de Réadaptation (CRR) in Sion and the Swiss paraplegic centre in Nottwil. They will be randomly divided into two groups, a first group of patients will undergo a conventional treatment of rehabilitation while a second set of patients will be treated using a brand new system of electro-stimulation called MotionMaker TM. Biopsies will be obtained in the first weeks after admission; two other biopsies will be taken respectively 3 and 6 months post-lesion. For each group, the muscle biopsies will be divided into 4 samples which will be used for a) real-time PCR to quantify the gene expression of the different components of the ubiquitin-proteasome system (Atrogin-1, MuRF1, Nedd4, UBB and Psma) b) Western blotting, using anti-phospho-site specific antibodies to quantify the activities of the Akt/GSK3 and Akt/mTOR pathways and of their downstream regulators of protein synthesis, eIF2B, p70S6K and PHAS-1/4E-BP1 c) fiber type analysis to quantify the variation in MHC expression and d) immunochemistry to localize the investigators molecular targets inside the different fiber types.

Expected value of the proposed project Our results will provide an increased understanding of the molecular mechanisms contributing to skeletal muscle atrophy during the early stages following SCI and a characterization of the impact of endurance training in the no more voluntary innervated muscle. Moreover this study will also investigate the potential improvement in the rehabilitation process by using a new system of electro-stimulation.


Condition Intervention
Spinal Cord Injuries
Muscle Atrophy
Procedure: Motionmaker

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy

Resource links provided by NLM:


Further study details as provided by Clinique Romande de Readaptation:

Primary Outcome Measures:
  • Signaling pathways in human muscles after spinal cord injury [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Muscle biopsy of the vastus lateralis


Secondary Outcome Measures:
  • Muscle strength [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    leg circumference and power output on the Motionmaker

  • Spacity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Reduction of spasticity


Estimated Enrollment: 28
Study Start Date: May 2010
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Training Procedure: Motionmaker
3 times per week, FES Training on the Motionmaker device, for 6 months

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • acute, motor complete SCI
  • lesion level C5-T12

Exclusion Criteria:

  • diabetes type I
  • pregnancy
  • oral anti-coagulation
  • osteosyntheses of the femur
  • hepatitis B,C or D
  • HIV
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01470950

Contacts
Contact: Michael E Baumberger, MD +41419395245 michael.baumberger@paranet.ch
Contact: Bertrand Léger, PhD +41792938876 bertrand.leger@crr-suva.ch

Locations
Switzerland
Swiss Paraplegic Centre Recruiting
Nottwil, Lucerne, Switzerland, 6207
Contact: Michael E Baumberger, MD     +41419395245     michael.baumberger@paranet.ch    
Principal Investigator: Michael E Baumberger, Dr. med.            
Clinique Romande de Réadaption Recruiting
Sion, Valais, Switzerland, 1951
Contact: Bertrand Léger, PhD     +41792938876     bertrand.leger@crr-suva.ch    
Principal Investigator: Bertrand Léger, PhD            
Sponsors and Collaborators
Clinique Romande de Readaptation
Swiss Paraplegic Centre Nottwil
Investigators
Principal Investigator: Bertrand Léger, PhD CRR Sion
Principal Investigator: Michael E Baumberger, MD Swiss Paraplegic Centre Nottwil
  More Information

No publications provided

Responsible Party: Bertrand LEGER, PhD, Scientific Collaborator, Clinique Romande de Readaptation
ClinicalTrials.gov Identifier: NCT01470950     History of Changes
Other Study ID Numbers: MMStudy
Study First Received: September 21, 2011
Last Updated: January 30, 2012
Health Authority: Switzerland: Ethical Committee of Lucerne

Keywords provided by Clinique Romande de Readaptation:
Functional Electrical Stimulation
Signalling Pathways

Additional relevant MeSH terms:
Muscular Atrophy
Spinal Cord Injuries
Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathological Conditions, Anatomical
Signs and Symptoms
Spinal Cord Diseases
Central Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries

ClinicalTrials.gov processed this record on May 19, 2013